All Q2 FY26 results →

GM

Globus Medical, Inc.

Q2 FY26Health Care Equipment and Supplies

Globus Medical, Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹82

Market cap₹11.2K Cr

P/E19.9

Updated30 May 2026

Read3 min read

What the Q2 FY26 call signalled

2 of 3 strong

RevenueModerate growth

MarginMargins up

CapexCapex planned

The short version

- U.S. - Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025.

From Globus Medical, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.

Revenue & Sales Performance

Moderate growth

U.S. Spine business expected to continue strong growth, with recent quarters showing around 10% growth, driven mainly by market share gains.
International Spine business targeting a return to consistent low double-digit growth (around 10% constant currency), with mid-teens growth seen recently influenced by currency and prior-year supply chain disruptions. Long term, international growth expected in the low to mid-double-digit range (12%-15%), focusing on deeper market penetration rather than expanding into new countries.
Enabling Technologies business growing, with 21% revenue increase in Q1 2026, but shifting to more flexible offerings (leases/rentals) possibly moderating upfront revenue recognition.
Trauma and neuromonitoring businesses showing strong growth (over 30%).

2 more points from Globus Medical, Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025.
Non-GAAP diluted EPS guidance was raised to $4.70 to $4.80 from $4.40 to $4.50, implying 18.1% to 20.6% growth over 2025.
EPS growth is driven by margin expansion (gross profit margin sustained above 69% in Q1) and operating leverage from sales growth.
Management expects continued gross margin improvements, targeting mid-70% gross margin long term with ongoing supply chain and manufacturing initiatives.

2 more points from Globus Medical, Inc.'s call on margins

Create a free account to keep reading this call

See what Globus Medical, Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Capital expenditures were $39.6 million in the recent quarter, representing 5.2% of sales.
Capital allocation priorities remain:
Internal investment in innovative product development.
Capital spending on building sets for global sales force.
Investments in facilities, machinery, and equipment to expand manufacturing footprint.
Continued share repurchase program with $390 million remaining authorized as of March 31, 2026.
Ongoing evaluation of complementary M&A focused on investments driving long-term profitable growth.

2 more points from Globus Medical, Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

Company has $799.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
Existing share repurchase program of $500 million initiated in Q2 2025; $110 million purchased so far with $390 million remaining.
Capital allocation priorities include internal investment in product development, supporting sales force expansion, manufacturing investments, share repurchases, and evaluating complementary M&A.

2 more points from Globus Medical, Inc.'s call on fundraising

Create a free account to keep reading this call

See what Globus Medical, Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights related to demand and sales outlook include: - The company is experiencing strong demand, with U.S. Spine and International Spine businesses growing well. - There is a focus on growing implant procedures driven by robotic system placements and training. - The Enabling Technology segment is shifting towards more rental/leasing models, which creates a larger pipeline but affects upfront revenue recognition.

2 more points from Globus Medical, Inc.'s call on order book

Create a free account to keep reading this call

Others in Health Care Equipment and Supplies this season

Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Zimmer Biomet Holdings, Inc. (Q2 FY26)
Zimmer Biomet Holdings, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $16,023, P/E 21.9. AI-powered earnings insights.

Compare:vs Intuitive Surgical, Inc.vs Stryker Corporation vs Medtronic plc

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Globus Medical, Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Globus Medical, Inc. Q2 FY26 results?

- U.S. - Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025.

What is Globus Medical, Inc. share price analysis?

Globus Medical, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 19.9 with a market cap of $11,192. Investors should review the full earnings analysis for detailed insights.

Is Globus Medical, Inc. planning capital expenditure?

- Capital expenditures were $39.6 million in the recent quarter, representing 5.2% of sales.

Keep Globus Medical, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.